Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study
暂无分享,去创建一个
E. Brendel | O. Gallego | J. Broto | A. López-pousa | R. Cubedo | X. G. Muro | Ò. M. Tirado | J. Martín-Liberal | O. Tirado
[1] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[2] P. Casali,et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] W. Guo,et al. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway , 2010, Journal of surgical oncology.
[4] S. Sleijfer,et al. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies , 2010, British Journal of Cancer.
[5] M. Ratain,et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial , 2011, Investigational New Drugs.
[6] G. Camussi,et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways , 2009, Molecular Cancer.
[7] Tao Ji,et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway , 2009, Cancer biology & therapy.
[8] A. D. Van den Abbeele,et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Patrick Schöffski,et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Qin,et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Bergh,et al. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling , 2008, OncoTargets and therapy.
[12] S. Singer,et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells , 2008, Molecular Cancer Therapeutics.
[13] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[14] O. S. Nielsen,et al. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.
[15] J. Maurel,et al. A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma , 2005, Cancer.
[16] R. Maki,et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] O. S. Nielsen,et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. , 2002, European journal of cancer.
[18] O. S. Nielsen,et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.
[19] J. Blay,et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.
[20] K. Müller,et al. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours , 2000, Journal of Cancer Research and Clinical Oncology.
[21] C. Zornig,et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma , 1999, Journal of Cancer Research and Clinical Oncology.
[22] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.
[23] A. Antón,et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] K. Hillan,et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. , 1996, Cancer research.
[25] J. Verweij,et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Edmonson,et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Verweij,et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] G. Bonadonna,et al. Phase II evaluation of adriamycin in human neoplasia , 1973, Cancer.